Evidence map›Paper›PMID 34556983›Full record

ArticleInternational journal of chronic obstructive pulmonary disease

The rs74794265 SNP of the

Zulipikaer Abudureheman, Li Li, XueMei Zhong, JingRan Xu, Hui Gong, Subinuer Yilamujiang, Jie Ren, ChengXin Xie, AiFang Zheng, Dilala Tuerxun and 4 more

Open access · goldAbstract read
In one paragraph

Article in International journal of chronic obstructive pulmonary disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Annals of medicine · 2025
    Article
  5. Article
  6. Article
  7. Role of Genetic Polymorphisms inInternational journal of chronic obstructive pulmonary disease · 2022
    Article
  8. Whole-Exome Sequencing Implicates theFrontiers in cell and developmental biology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Zulipikaer Abudureheman *Department of Clinical Research Center of Infectious Diseases (Pulmonary Tuberculosis), First People's Hospital of Kashi, Kashi, People's Republic of China.
Li Li *Department of Respiratory and Critical Care Medicine, First People's Hospital of Kashi, Kashi, People's Republic of China.
XueMei Zhong *Department of Respiratory and Critical Care Medicine, First People's Hospital of Kashi, Kashi, People's Republic of China.
JingRan XuDepartment of Respiratory and Critical Care Medicine, First People's Hospital of Kashi, Kashi, People's Republic of China.
Hui GongDepartment of Clinical Research Center of Infectious Diseases (Pulmonary Tuberculosis), First People's Hospital of Kashi, Kashi, People's Republic of China.
Subinuer YilamujiangDepartment of Clinical Research Center of Infectious Diseases (Pulmonary Tuberculosis), First People's Hospital of Kashi, Kashi, People's Republic of China.
Jie RenDepartment of Respiratory and Critical Care Medicine, First People's Hospital of Kashi, Kashi, People's Republic of China.
ChengXin XieDepartment of Respiratory and Critical Care Medicine, First People's Hospital of Kashi, Kashi, People's Republic of China.
AiFang ZhengDepartment of Respiratory and Critical Care Medicine, First People's Hospital of Kashi, Kashi, People's Republic of China.
Dilala TuerxunDepartment of Respiratory and Critical Care Medicine, First People's Hospital of Kashi, Kashi, People's Republic of China.
Ayiguzali AbudukadeerDepartment of Respiratory and Critical Care Medicine, First People's Hospital of Kashi, Kashi, People's Republic of China.
Paierda AiniDepartment of Respiratory and Critical Care Medicine, First People's Hospital of Kashi, Kashi, People's Republic of China.
AiMin XuDepartment of Clinical Laboratory, First People's Hospital of Kashi, Kashi, People's Republic of China.
XiaoGuang ZouDepartment of Respiratory and Critical Care Medicine, First People's Hospital of Kashi, Kashi, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKashi city is situated near the Taklamakan desert and has a high incidence rate of chronic obstructive pulmonary disease (COPD). In this study, we aimed to explore the relationship between the SNP of the

methodsA total of 541 patients with COPD and 534 control subjects were included in this study. Sanger sequencing was used to analyze the SNP of the

resultsThe

conclusionWe found that the rs74794265 heterozygous C/T genotype significantly reduces the risk of COPD. The C/T genotype is likely a protective factor for COPD in the Kashi region. We speculate that the occurrence of COPD in this area is probably more related to desert climate condition and genetic factors than smoking status.

Indexed as

Genetic Predisposition to DiseasePulmonary Disease, Chronic ObstructiveCase-Control StudiesChinaGene FrequencyGenotypeHumansPolymorphism, Single NucleotideSerine-Arginine Splicing FactorsSerine-Arginine Splicing FactorsSREK1 protein, humanCOPDrs74794265 locusSREK1 gene polymorphismUyghur population

Identifiers

PMID34556983
PMCPMC8453436
OpenAlexW3201187696

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.